Recludix Pharma is a clinical-stage biopharmaceutical company developing platform-based approaches to discover potent and selective inhibitors of challenging protein targets, with a focus on SH2 domain-containing proteins. The company's proprietary platform integrates structural biology, computational chemistry, and medicinal chemistry to tackle previously elusive but biologically validated targets. Recludix's lead programs target STAT6 and BTK for inflammatory diseases and oncology indications. The company was recognized as a Fierce 15 Biotech Company in 2024.
Tech & App Stack is available on paid plans
Upgrade to Silver or higher to reveal the full technology and app stack for any company.
View pricingCreate a free account to see funding visualizations and detailed round data.
Create Free AccountJan 2026
Nov 2021
Create a free account to see which investors have funded this company.
Create Free Account
Global contract development and manufacturing organization (CDMO) focused exclusively on sterile ...
AI-first drug discovery company using AlphaFold-derived models to design therapeutics and acceler...
Food technology company creating plant-based meat and dairy products that replicate the taste and...
Asymchem provides R&D and one-stop production services to the world's top pharmaceutical companies.
South Korean biotech company and global leader in medical aesthetics, manufacturing botulinum tox...
Global full-service clinical research organization (CRO) and scientific advisory partner for biot...
